Toggle navigation
Home
Products
Dexolve
Services
Feasibility
Pipeline
News
Staff
Career
Search
Log In / Register
€
$
News
Sucampo has aquired Vtesse
News
5 July, 2017
Sucampo Pharmaceuticals Inc., a global biopharmaceutical company has aquired Vtesse, rare disease company.
Sucampo will accelerate the development and potential commercialization of VTS-270 (2-hydroxypropyl-beta-cyclodextrin with a defined compositional fingerprint), now in a pivotal clinical trial for the treatment of Niemann Pick type C disease. The Vtesse team joined Sucampo to continue supporting the advancement of VTS-270.
Link
BACK TO NEWS